Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
about
Explaining variability in ciclosporin exposure in adult kidney transplant recipients.Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients.Impact of citrus soft drinks relative to grapefruit juice on ciclosporin dispositionSafety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolismPharmacogenetic differences and drug-drug interactions in immunosuppressive therapy.Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.PharmGKB summary: very important pharmacogene information for CYP3A5.Cytochrome P450 variations in different ethnic populations.Therapeutic drug monitoring in pediatric renal transplantation.Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening.The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation.Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week.
P2860
Q33847140-3451FF62-1D6C-45DB-ADDE-0A54E41EA685Q35157102-9C3E1F6D-23B0-43F8-9EA0-5CF7F8773420Q35827797-5DFC7669-DEE3-4B27-8568-B38F20F6FE9DQ36271648-1851B0DF-AB09-4879-8B0D-5DD74A224163Q36410101-17DBE95F-EAA7-42A6-85AF-A80BADEC6D0DQ36535923-11AB1AAC-8370-4FF4-8B3E-D8A60B1F6685Q36544981-97FC8BFA-B2C3-4CEA-8D62-42EB446CEDE3Q37074093-43D61CA2-BDF9-4A60-B7B8-C37523A720B0Q37081741-23471177-875A-4D82-B27F-BB265618D498Q37979866-FE9CFCF4-1569-462A-88DB-7AED01D7A9C5Q38206952-9079485C-F406-444E-8957-4E2D7909CFA8Q39420843-29D41E76-C052-47D0-A5AB-AC8E3D18DFD5Q40473486-B1A5C955-2467-45F7-99E5-F27016272965Q41666716-43B2DC93-B035-4C1B-A586-55F925980AD7Q41994948-AC5434D1-2AE6-40A8-85B2-180EA6BF97F4Q44035338-54AFBF15-B01F-4AEC-9EDF-9A1326B97FE0Q52903712-DED88DE4-C9C3-4C6A-A7DA-868B26328296
P2860
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
@ast
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
@en
type
label
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
@ast
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
@en
prefLabel
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
@ast
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
@en
P2093
P2860
P356
P1433
P1476
Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
@en
P2093
Christopher Legendre
Dany Anglicheau
Eric Thervet
Philippe Beaune
P2860
P356
10.1517/14622416.6.1.37
P577
2005-01-01T00:00:00Z